Amphastar Pharmaceuticals Explained
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[4] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[5]
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[6] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[6]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[7]
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.[8] [9]
See also
- List of S&P 600 companies
Notes and References
- Web site: U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc.. U.S. Securities and Exchange Commission. July 31, 2023.
- Web site: Amphastar Pharmaceuticals Inc . 2024-03-19 . Bloomberg.
- Web site: Amphastar Pharmaceuticals, Inc. (AMPH) Income Statement - Yahoo Finance . 2024-03-19 . finance.yahoo.com . en-US.
- Web site: Amphastar Pharmaceuticals, Inc. (AMPH). NASDAQ.com. NASDAQ OMX Group. 3 January 2016.
- Web site: Profile:Amphastar Pharmaceuticals Inc (AMPH.O). Reuters.
- News: Arsalan. Arif. After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version. Endpoints. February 21, 2017.
- Web site: Raymond . Nate . June 19, 2019 . Momenta, Amphastar settle generic Lovenox drug patent case . March 14, 2024 . Reuters.
- Web site: Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash . 2023-04-26 . Yahoo Finance . 24 April 2023 . en-US.
- Web site: Amphastar buys Baqsimi to build out specialty med offering . 2023-04-26 . www.thepharmaletter.com.
